The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pneumococcal Vaccine Polyvalent Market Research Report 2024
Synopsis
Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis.
The global Pneumococcal Vaccine Polyvalent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Vaccine Polyvalent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumococcal Vaccine Polyvalent.
Report Scope
The Pneumococcal Vaccine Polyvalent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Vaccine Polyvalent market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Vaccine Polyvalent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co.
Pfizer
Segment by Type
Prevnar 13
Pneumovax23
Segment by Application
18 Years and Younger
19 To 64 Years Old
65 Years and Older
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pneumococcal Vaccine Polyvalent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis.
The global Pneumococcal Vaccine Polyvalent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Vaccine Polyvalent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumococcal Vaccine Polyvalent.
Report Scope
The Pneumococcal Vaccine Polyvalent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Vaccine Polyvalent market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Vaccine Polyvalent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck & Co.
Pfizer
Segment by Type
Prevnar 13
Pneumovax23
Segment by Application
18 Years and Younger
19 To 64 Years Old
65 Years and Older
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pneumococcal Vaccine Polyvalent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pneumococcal Vaccine Polyvalent Market Overview
1.1 Product Overview and Scope of Pneumococcal Vaccine Polyvalent
1.2 Pneumococcal Vaccine Polyvalent Segment by Type
1.2.1 Global Pneumococcal Vaccine Polyvalent Market Value Comparison by Type (2024-2030)
1.2.2 Prevnar 13
1.2.3 Pneumovax23
1.3 Pneumococcal Vaccine Polyvalent Segment by Application
1.3.1 Global Pneumococcal Vaccine Polyvalent Market Value by Application: (2024-2030)
1.3.2 18 Years and Younger
1.3.3 19 To 64 Years Old
1.3.4 65 Years and Older
1.4 Global Pneumococcal Vaccine Polyvalent Market Size Estimates and Forecasts
1.4.1 Global Pneumococcal Vaccine Polyvalent Revenue 2019-2030
1.4.2 Global Pneumococcal Vaccine Polyvalent Sales 2019-2030
1.4.3 Global Pneumococcal Vaccine Polyvalent Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pneumococcal Vaccine Polyvalent Market Competition by Manufacturers
2.1 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pneumococcal Vaccine Polyvalent Average Price by Manufacturers (2019-2024)
2.4 Global Pneumococcal Vaccine Polyvalent Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Product Type & Application
2.7 Pneumococcal Vaccine Polyvalent Market Competitive Situation and Trends
2.7.1 Pneumococcal Vaccine Polyvalent Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pneumococcal Vaccine Polyvalent Players Market Share by Revenue
2.7.3 Global Pneumococcal Vaccine Polyvalent Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pneumococcal Vaccine Polyvalent Retrospective Market Scenario by Region
3.1 Global Pneumococcal Vaccine Polyvalent Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pneumococcal Vaccine Polyvalent Global Pneumococcal Vaccine Polyvalent Sales by Region: 2019-2030
3.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2019-2024
3.2.2 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2025-2030
3.3 Global Pneumococcal Vaccine Polyvalent Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2019-2030
3.3.1 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2019-2024
3.3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2025-2030
3.4 North America Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
3.4.1 North America Pneumococcal Vaccine Polyvalent Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pneumococcal Vaccine Polyvalent Sales by Country (2019-2030)
3.4.3 North America Pneumococcal Vaccine Polyvalent Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
3.5.1 Europe Pneumococcal Vaccine Polyvalent Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pneumococcal Vaccine Polyvalent Sales by Country (2019-2030)
3.5.3 Europe Pneumococcal Vaccine Polyvalent Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
3.6.1 Asia Pacific Pneumococcal Vaccine Polyvalent Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pneumococcal Vaccine Polyvalent Sales by Country (2019-2030)
3.6.3 Asia Pacific Pneumococcal Vaccine Polyvalent Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
3.7.1 Latin America Pneumococcal Vaccine Polyvalent Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pneumococcal Vaccine Polyvalent Sales by Country (2019-2030)
3.7.3 Latin America Pneumococcal Vaccine Polyvalent Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pneumococcal Vaccine Polyvalent Market Facts & Figures by Country
3.8.1 Middle East and Africa Pneumococcal Vaccine Polyvalent Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pneumococcal Vaccine Polyvalent Sales by Type (2019-2030)
4.1.1 Global Pneumococcal Vaccine Polyvalent Sales by Type (2019-2024)
4.1.2 Global Pneumococcal Vaccine Polyvalent Sales by Type (2025-2030)
4.1.3 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2019-2030)
4.2 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2019-2030)
4.2.1 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2019-2024)
4.2.2 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2025-2030)
4.2.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2019-2030)
4.3 Global Pneumococcal Vaccine Polyvalent Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pneumococcal Vaccine Polyvalent Sales by Application (2019-2030)
5.1.1 Global Pneumococcal Vaccine Polyvalent Sales by Application (2019-2024)
5.1.2 Global Pneumococcal Vaccine Polyvalent Sales by Application (2025-2030)
5.1.3 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2019-2030)
5.2 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2019-2030)
5.2.1 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2019-2024)
5.2.2 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2025-2030)
5.2.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2019-2030)
5.3 Global Pneumococcal Vaccine Polyvalent Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck & Co.
6.1.1 Merck & Co. Corporation Information
6.1.2 Merck & Co. Description and Business Overview
6.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio
6.1.5 Merck & Co. Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pneumococcal Vaccine Polyvalent Industry Chain Analysis
7.2 Pneumococcal Vaccine Polyvalent Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pneumococcal Vaccine Polyvalent Production Mode & Process
7.4 Pneumococcal Vaccine Polyvalent Sales and Marketing
7.4.1 Pneumococcal Vaccine Polyvalent Sales Channels
7.4.2 Pneumococcal Vaccine Polyvalent Distributors
7.5 Pneumococcal Vaccine Polyvalent Customers
8 Pneumococcal Vaccine Polyvalent Market Dynamics
8.1 Pneumococcal Vaccine Polyvalent Industry Trends
8.2 Pneumococcal Vaccine Polyvalent Market Drivers
8.3 Pneumococcal Vaccine Polyvalent Market Challenges
8.4 Pneumococcal Vaccine Polyvalent Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
